YunW.OhMD

Oncology • Silver Spring, MD

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Physician

Join to view full profile

Dr. Oh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Oh's full profile

Already have an account?

Office
10903 New Hampshire Avenue
Silver Spring, MD 20993

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1997 - 2000
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1994 - 1996
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1992 - 1994
George Washington UniversityResidency, Surgery, 1989 - 1992
Butler HospitalInternship, Transitional Year, 1988 - 1989
The Warren Alpert Medical School of Brown UniversityClass of 1988
Yale UniversityBA

Certifications & Licensure

MD State Medical License 2008 - 2025
DC State Medical License 1992 - 2020
VA State Medical License 2017 - 2020
TX State Medical License 2001 - 2010

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
Clifton Howe Award for clinical excellence 1998

Clinical Trials

Mode of Dialysis Therapy and Outcomes in End Stage Renal Disease (ESRD) Start of enrollment: 2009 Jul 01
Active, not recruiting

Publications & Presentations

PubMed

22 citations
Randomized, Double-Blind, Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non–...
Pasi A. Jänne, Luis Paz-Ares, Yun Oh, C. Eschbach, Vera Hirsh
Journal of Thoracic Oncology. 2014-01-01
18 citations
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patie...
Hai T. Tran, Ralph Zinner, George R. Blumenschein, Y. Oh, Vassiliki A. Papadimitrakopoulou
Investigational New Drugs. 2011-06-01
95 citations
Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases
Yun Oh, Sarah H. Taylor, Benjamin N. Bekele, J. Matthew Debnam, Pamela K. Allen
Cancer. 2009-07-01

Books/Book Chapters

Targeted Therapies in Oncology: Clinical Achievements
Chapter: Protein Kinase C Inhibitors in the Treatment of Non-Small Cell Lung Cancer
Oh Y and Lahn MEditors: Giaccone G & Soria JC.Taylor & Francis2007
Oncologic Therapies
Chapter: A Brief Review of Cancer Chemoprevention
Oh Y and Papadimitrakopoulou VEditors: Vokes EE & Golomb HM.Springer-Verlag1999
PCR Applications – Protocols for Functional Genomics
Chapter: Microsatellite Protocols
Oh Y and Mao LiEditors: Innis MA, Gelfand DH, Sninsky JJ.Academic Press1999

Committees

Chair, Glioblastoma Astrocytoma ETP's (Evidence Based Treatment Protocols) for CCE 2012 - Present
Chair, Melanoma ETP's (Evidence Based Treatment Protocols) for CCE 2012 - Present
Co-chair, Lung Cancer ETP's (Evidence Based Treatment Protocol) for CCE 2011 - Present
Chair, Head & Neck Cancer ETP's (Evidence Based Treatment Protocols) for CCE 2011 - Present
member, Clinical Quality Control Committee for CCE (Cancer Centers of Excellence) 2009 - Present
volunteer, Minority Health Fair - Asian American Center of Frederick, under Ms. Elizabeth Chung 2009 - Present

Other Languages

Korean, Spanish, French